These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 15555412)

  • 21. Influenza vaccines purified by zonal ultracentrifugation.
    Filczak K; Semkow R; Wrzos H; Zakrzewski K; Zgorzelska K
    Acta Microbiol Pol A; 1973; 5(3):261-70. PubMed ID: 4769561
    [No Abstract]   [Full Text] [Related]  

  • 22. Influenza 1980-1.
    Br Med J; 1980 Aug; 281(6239):527-8. PubMed ID: 7427354
    [No Abstract]   [Full Text] [Related]  

  • 23. Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children.
    Vajo Z; Kosa L; Szilvasy I; Pauliny Z; Bartha K; Visontay I; Kis A; Tarjan I; Rozsa N; Jankovics I
    Pediatr Infect Dis J; 2008 Dec; 27(12):1052-6. PubMed ID: 18978514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of the antiinfluenza A vaccination during epidemics due to A/VIC/3/75 and A/Texas/1/77 viruses.
    Aymard M; Bentejac MC; Larbaigt G; Michaut D; Triau R
    Dev Biol Stand; 1979; 43():231-9. PubMed ID: 520670
    [No Abstract]   [Full Text] [Related]  

  • 25. [Research on the immunity against influenza in the population of Milan in the fall of 1972. Distribution of h.i.a. (hemagglutination inhibition antibodies) against A-Hong Kong-68 and A-England-42-72 viruses and the immunizing effectiveness of current vaccines].
    Profeta ML; Bergamini F
    Boll Ist Sieroter Milan; 1973; 52(1):25-31. PubMed ID: 4714450
    [No Abstract]   [Full Text] [Related]  

  • 26. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
    Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
    Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of the reactogenic and immunogenic properties of the influenza subunit polyvalent vaccine Grippovac SE-AZh during the immunization of schoolchildren].
    Slepushkin AN; Obrosova-Serova NP; Feklisova LV; Bebisheva NI; Mel'nikova SK
    Vestn Akad Med Nauk SSSR; 1984; (1):75-9. PubMed ID: 6711101
    [No Abstract]   [Full Text] [Related]  

  • 28. [Preventive influenza vaccination--possibilities and limits in the prevention of influenza-virus infections].
    Wesselius-de Casparis A
    Med Monatsschr; 1973 Oct; 27(10):447-9. PubMed ID: 4777787
    [No Abstract]   [Full Text] [Related]  

  • 29. [Antigenicity of various influenza vaccines in man].
    Kuwert E; Höhner PG; Bertrams J; Schriever O
    Dtsch Med Wochenschr; 1971 May; 96(22):938-45. PubMed ID: 4325348
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs.
    Kyriakis CS; De Vleeschauwer A; Barbé F; Bublot M; Van Reeth K
    Vaccine; 2009 Apr; 27(16):2258-64. PubMed ID: 19428840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease.
    Holvast A; Huckriede A; Wilschut J; Horst G; De Vries JJ; Benne CA; Kallenberg CG; Bijl M
    Ann Rheum Dis; 2006 Jul; 65(7):913-8. PubMed ID: 16322083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children.
    Chiu SS; Peiris JS; Chan KH; Wong WH; Lau YL
    Pediatrics; 2007 Jun; 119(6):1076-82. PubMed ID: 17545373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Editorial: Inactivated influenza vaccines.
    Dowdle WR
    N Engl J Med; 1973 Dec; 289(24):1309-10. PubMed ID: 4127184
    [No Abstract]   [Full Text] [Related]  

  • 34. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
    Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
    J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statement on influenza vaccination for the 1991-92 season.
    CMAJ; 1991 Sep; 145(5):465-9. PubMed ID: 1878828
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
    Avila Aguero ML; Soriano-Fallas A; Umaña-Sauma MA; Ulloa-Gutierrez R; Arnoux S
    Medicina (B Aires); 2007; 67(4):351-9. PubMed ID: 17891930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
    Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An influenza A/H3 outbreak during the 2004/2005 winter in elderly vaccinated people living in a nursing home.
    Iorio AM; Neri M; Lepri E; Camilloni B; Basileo M; Sigismondi N; Fabiani C; Calzoletti L; Puzelli S; Donatelli I
    Vaccine; 2006 Nov; 24(44-46):6615-9. PubMed ID: 16828941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunity and influenza virus].
    Melino C
    Clin Ter; 1988 Sep; 126(5):353-62. PubMed ID: 2973965
    [No Abstract]   [Full Text] [Related]  

  • 40. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
    Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE
    Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.